Good news! Cancer is history (soon)!
"An mRNA vaccine to treat the deadliest form of skin cancer has met a major milestone on the path to a new treatment, according to clinical trial results released today by Merck and Moderna.
If approved by the FDA, it would become the first ever mRNA-based cancer treatment and pave the way for similar treatments for other cancers—representing “the next frontier of cancer immunotherapy,” ...
Phase 3 clinical trial results showed that the experimental drug—intismeran autogene—prevented recurrence and metastasis of removed melanoma tumors when combined with the immunotherapy Keytruda. The companies have not released the full phase 3 results, but earlier phase 2 trials reported that risk of recurrence or death was reduced by nearly half after five years. ..."
"First and only combination regimen to demonstrate statistically significant and clinically meaningful improvements in RFS and DMFS compared to KEYTRUDA alone for these patients in the adjuvant melanoma setting
The Companies plan to present data at an upcoming international medical meeting and will engage with regulators on filing submissions for intismeran autogene in combination with KEYTRUDA
Intismeran autogene is an mRNA-based individualized neoantigen therapy (INT) designed specifically for each patient based on the unique set of mutations within their tumor to train and activate the immune system to recognize and fight cancer
...
The trial met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS). This represents the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy, as well as the first Phase 3 study to demonstrate a clinically meaningful improvement over KEYTRUDA alone, a standard-of-care immunotherapy, in the adjuvant setting for patients with resected melanoma. ..."
No comments:
Post a Comment